phrykt

Contineum Therapeutics, Inc. (CTNM): who owns it and who trades it

As of Nov 16, 2026, CTNM insiders reported 30 open-market sales worth $1.9M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Daniel S. Lorrain (Chief Scientific Officer), with $1.1M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Contineum Therapeutics

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CTNM

102 funds and institutions reported CTNM shares worth $504M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Montanova Capital, LLC with 12.3%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Montanova Capital, LLC12.3%
Jupiter Topco LLC11.8%
BlackRock, Inc.8.9%
Johnson & Johnson8.6%
Franklin Resources Inc8.0%
Balyasny Asset Management L.P.6.6%
Vanguard Capital Management LLC5.7%
Perceptive Advisors LLC5.4%
FMR LLC (Fidelity)4.5%
Millennium Management LLC4.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Montanova Capital, LLC2.84M12.30%$46.6MNo change
Jupiter Topco LLC2.73M11.84%$44.8MNew
BlackRock, Inc.2.06M8.94%$33.8M+209%
Johnson & Johnson1.98M8.57%$32.4MNo change
Franklin Resources Inc1.84M7.96%$30.1MNo change
Balyasny Asset Management L.P.1.52M6.59%$25M-10%
Vanguard Capital Management LLC1.32M5.72%$21.7M+9%
Perceptive Advisors LLC1.26M5.44%$20.6MNo change
FMR LLC (Fidelity)1.04M4.50%$17M+28%
Millennium Management LLC931,7094.03%$15.3M-39%
Great Point Partners LLC921,4813.99%$15.1M+15%
Longaeva Partners L.P.812,7573.52%$13.3M+11%
Ikarian Capital, LLC807,8743.50%$13.2MNo change
Sectoral Asset Management Inc727,5873.15%$11.9MNo change
Geode Capital Management, LLC693,1883.00%$11.4M+146%
Hhlr Advisors, Ltd.669,3372.90%$11MNo change
Red Tree Management, LLC638,1582.76%$10.5MNo change
Versant Venture Management, LLC542,6282.35%$8.9MNo change
Goldman Sachs Group Inc497,2552.15%$8.2M+62%
Boxer Capital Management, LLC494,0002.14%$8.1MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CTNM insiders reported $0 of open-market purchases and $1.9M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$1.9M
30 trades, 3 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Sep 8, 2026
Filed Sep 8, 2026

Purchases and sales by month

$851K$851KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 8, 2026Carmine N. StengoneCEOSale plan2,500$16.46$41.1KForm 4
Aug 3, 2026Carmine N. StengoneCEOSale plan2,500$16.01$40KForm 4
Jul 9, 2026Daniel S. LorrainChief Scientific OfficerSale plan25$16.00$400Form 4
Jul 8, 2026Daniel S. LorrainChief Scientific OfficerSale plan1,015$16.00$16.2KForm 4
Jul 8, 2026Carmine N. StengoneCEOSale plan2,500$16.00$40KForm 4
Jul 1, 2026Daniel S. LorrainChief Scientific OfficerSale plan2,501$16.24$40.6KForm 4
Jul 1, 2026Daniel S. LorrainChief Scientific OfficerSale plan5,852$15.67$91.7KForm 4
Jun 30, 2026Daniel S. LorrainChief Scientific OfficerSale plan28,826$16.04$462KForm 4
Jun 30, 2026Tim WatkinsCMO & Head of DevelopmenSale plan10,833$16.02$174KForm 4
Jun 30, 2026Carmine N. StengoneCEOSale plan10,000$16.01$160KForm 4
Jun 1, 2026Daniel S. LorrainChief Scientific OfficerSale plan4,170$13.16$54.9KForm 4
May 1, 2026Daniel S. LorrainChief Scientific OfficerSale plan300$13.84$4.2KForm 4
May 1, 2026Daniel S. LorrainChief Scientific OfficerSale plan3,870$13.06$50.5KForm 4
Apr 6, 2026Daniel S. LorrainChief Scientific OfficerSale plan4,170$13.43$56KForm 4
Mar 2, 2026Daniel S. LorrainChief Scientific OfficerSale plan4,170$15.01$62.6KForm 4
Mar 2, 2026Tim WatkinsCMO & Head of DevelopmenSale plan3,611$15.02$54.2KForm 4
Feb 25, 2026Carmine N. StengoneCEOSale plan2,700$16.02$43.3KForm 4
Feb 25, 2026Daniel S. LorrainChief Scientific OfficerSale plan3,824$16.01$61.2KForm 4
Feb 24, 2026Carmine N. StengoneCEOSale plan4,400$16.02$70.5KForm 4
Feb 24, 2026Daniel S. LorrainChief Scientific OfficerSale plan4,300$16.03$68.9KForm 4
Feb 19, 2026Daniel S. LorrainChief Scientific OfficerSale plan100$16.00$1.6KForm 4
Feb 11, 2026Carmine N. StengoneCEOSale plan400$16.00$6.4KForm 4
Feb 3, 2026Daniel S. LorrainChief Scientific OfficerSale plan3,000$14.82$44.5KForm 4
Feb 3, 2026Daniel S. LorrainChief Scientific OfficerSale plan1,170$15.25$17.8KForm 4
Jan 28, 2026Tim WatkinsCMO & Head of DevelopmenSale plan2,800$14.09$39.5KForm 4
Jan 28, 2026Tim WatkinsCMO & Head of DevelopmenSale plan811$14.48$11.7KForm 4
Jan 5, 2026Daniel S. LorrainChief Scientific OfficerSale plan3,670$10.35$38KForm 4
Jan 5, 2026Daniel S. LorrainChief Scientific OfficerSale plan500$11.13$5.6KForm 4
Dec 29, 2025Tim WatkinsCMO & Head of DevelopmenSale plan3,611$12.06$43.5KForm 4
Dec 23, 2025Daniel S. LorrainChief Scientific OfficerSale plan4,170$12.23$51KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Daniel S. LorrainChief Scientific Officer–$1.1MJul 9, 2026
Carmine N. StengoneCEO and President, Director–$401KSep 8, 2026
Tim WatkinsCMO & Head of Development–$323KJun 30, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CTNM short interest

3.70M CTNM shares are sold short. Over the last 12 reports the number of shares short went up 161%.

As of Oct 30, 2026, 3.70M CTNM shares were sold short, up 1.1% from the report before. At the average daily volume of 874,802 shares, buying them all back would take about 4.2 trading days (days to cover).

Shares short

3.70MMay 15Oct 304.04M

Days to cover

4.2May 15Oct 3015.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.70M–+1%874,8024.2
Oct 15, 20263.66M–+19%1.64M2.2
Sep 30, 20263.07M–+26%847,4703.6
Sep 15, 20262.44M–+4%352,1316.9
Aug 31, 20262.34M–+0%582,6944.0
Aug 14, 20262.34M–-17%524,0374.5
Jul 31, 20262.82M–+15%208,54913.5
Jul 15, 20262.44M–+14%333,6977.3
Jun 30, 20262.14M–+29%720,3713.0
Jun 15, 20261.65M–+16%217,8867.6
May 29, 20261.43M–+1%152,9559.4
May 15, 20261.42M6.14%-12%210,2496.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Contineum Therapeutics company events

Contineum Therapeutics filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Sep 14, 2026AnnouncementContineum Therapeutics, Inc. issued a press release in which it reported the results of the MOONLIGHT-1 Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of JNJ-5120/PIPE-307 as a monotherapy in adult participants with major depressive disorder. Filing
  3. Jul 30, 2026ResultsReleased financial results. Filing
  4. Jul 13, 2026AnnouncementShared information with investors. Filing
  5. Jun 26, 2026VoteReported shareholder vote results. Filing
  6. May 5, 2026ResultsReleased financial results. Filing
  7. Apr 30, 2026AnnouncementThe Company announced topline data from its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain. Filing
  8. Mar 5, 2026AnnouncementAs previously reported, on May 14, 2025, the Company entered into a Sales Agreement with Leerink Partners LLC, pursuant to which the Company may from time to time issue and sell through Leerink Partners, acting as the Company’s agent, up to $75 million of shares of the Company’s Class A common… Filing
  9. Jan 26, 2026LeadershipThe Board of Directors of Contineum Therapeutics, Inc. approved the Continuem Therapeutics, Inc. 2026 Employment Inducement Equity Incentive Plan. Filing
  10. Dec 15, 2025AgreementContineum Therapeutics, Inc., a Delaware corporation, entered into an Underwriting Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC, acting as representatives of the several underwriters named in the Underwriting Agreement, relating to the sale of 7,346,938 shares of the Company’s… Filing
  11. Dec 11, 2025AnnouncementThe Company submitted the details of its global Phase 2 clinical trial of PIPE-791 to treat patients with idiopathic pulmonary fibrosis (IPF) to the ClinicalTrials.gov Protocol Registration and Results System (PRS). Filing
  12. Nov 20, 2025AnnouncementContineum Therapeutics, Inc. issued a press release in which it reported topline data from its Phase 2 PIPE-307 VISTA trial for the treatment of relapsing-remitting multiple sclerosis. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Contineum Therapeutics financials

Famous investors that hold CTNM

4 of the 50 well-known investors we track reported holding CTNM in their latest 13F filing. The largest position is Israel Englander's, worth $10.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026775,324$10.4M0.0%-17%
Ken Griffin · Citadel AdvisorsQ3 2026221,692$3M0.0%-44%
Steve Cohen · Point72 Asset ManagementQ3 202623,550$316K0.0%-9%
Jim Simons · Renaissance TechnologiesQ3 202615,500$208K0.0%-77%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named CTNM in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A7.3%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A7.3%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A4.6%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A4.6%
Nov 6, 2026Johnson & Johnson Innovation - JJDC, Inc.13G/A5.6%
Nov 6, 2026Johnson & Johnson Innovation - JJDC, Inc.13G/A5.6%
Nov 5, 2026FMR LLC13G7.9%
Nov 5, 2026FMR LLC13G7.9%
Oct 28, 2026Squadron Master Fund LP13G5.1%
Oct 28, 2026Squadron Master Fund LP13G5.1%
Oct 28, 2026Franklin Templeton, Inc.13G/A5.2%
Oct 28, 2026Franklin Templeton, Inc.13G/A5.2%
Oct 22, 2026Trails Edge Capital Partners, LP13G5.1%
Oct 22, 2026Trails Edge Capital Partners, LP13G5.1%

Questions about Contineum Therapeutics, Inc. (CTNM) stock

Who owns the most CTNM stock?

The largest reported owner of Contineum Therapeutics, Inc. (CTNM) is Montanova Capital, LLC, with 12.3% of the company. In total, 102 funds and institutions reported holding CTNM at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are CTNM insiders buying or selling?

In the last 12 months, CTNM insiders reported no open-market purchases and 30 sales worth $1.9M. The latest trade was on Sep 8, 2026. See every trade.

What is the short interest in CTNM?

As of Oct 30, 2026, 3.70M CTNM shares were sold short, up 1.1% from the report before. At the average daily volume of 874,802 shares, buying them all back would take about 4.2 trading days (days to cover). See the history.

Which famous investors hold CTNM?

4 of the 50 well-known investors we track reported CTNM in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $10.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.